We are live on ! Find out more
TTNP

Titan Pharmaceuticals
TTNP

Delisted

TTNP was delisted on the 1st of October, 2025.

Back to rankings

19 hedge funds and large institutions have $660K invested in Titan Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 0 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

78% more capital invested

Capital invested by funds: $371K → $660K (+$289K)

0% less ownership

Funds ownership: 0.01% → 0.01% (-0%)

0% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 5

10% less funds holding

Funds holding: 21 → 19 (-2)

Holders
19
Holders Change
-2
Holders Change %
-9.52%
% of All Funds
0.42%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
7
Reduced
–
Closed
5
Calls
$65K
Puts
–
Net Calls
+$65K
Net Calls Change
+$44K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$268K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$93.9K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$82.8K
4
Northern Trust
Northern Trust
Illinois
+$18.9K
5
ECM
ETrade Capital Management
Virginia
+$13.3K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$62K
2
Deutsche Bank
Deutsche Bank
Germany
-$35K
3
TSS
Two Sigma Securities
New York
-$5K
4
BWA
Beam Wealth Advisors
Louisiana
-$2K
5
Simplex Trading
Simplex Trading
Illinois
-$469

TTNP Hedge Fund Activity: Q1 2020 in Review

19 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q1 2020, worth a combined $660K — up 78% from $371K a quarter earlier.

Fund positioning in TTNP was balanced in Q1 2020: 5 funds opened new positions, 5 closed out, 7 added to existing stakes and 0 trimmed.

The largest buyer was Vanguard Group, adding an estimated $268K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $62K sold.

  • 19 institutional investors held Titan Pharmaceuticals (TTNP) as of Q1 2020, down from 21 in Q4 2019.
  • Funds reported $660K of Titan Pharmaceuticals stock for Q1 2020, up 78% quarter-over-quarter.
  • 5 funds opened new Titan Pharmaceuticals positions in Q1 2020 and 5 closed out, a net change of 0 holders.
  • The largest Titan Pharmaceuticals buyer in Q1 2020 was Vanguard Group, an estimated $268K added.
  • The largest Titan Pharmaceuticals seller in Q1 2020 was Renaissance Technologies, an estimated $62K sold.

Based on aggregated 13F filings for Q1 2020.